| Neuron-specific enolase as a biomarker: biochemical and clinical aspects MA Isgrò, P Bottoni, R Scatena Advances in cancer biomarkers: from biochemistry to clinic for a critical …, 2015 | 548 | 2015 |
| CA 19-9: biochemical and clinical aspects S Scarà, P Bottoni, R Scatena Advances in Cancer Biomarkers: From biochemistry to clinic for a critical …, 2015 | 314 | 2015 |
| The multiple functions of hemoglobin B Giardina, I Messana, R Scatena, M Castagnola Critical reviews in biochemistry and molecular biology 30 (3), 165-196, 1995 | 258 | 1995 |
| The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic R Scatena, P Bottoni, G Botta, GE Martorana, B Giardina American journal of physiology-cell physiology 293 (1), C12-C21, 2007 | 229 | 2007 |
| The role of CA 125 as tumor marker: biochemical and clinical aspects P Bottoni, R Scatena Advances in Cancer Biomarkers: From biochemistry to clinic for a critical …, 2015 | 227 | 2015 |
| Glycolytic enzyme inhibitors in cancer treatment R Scatena, P Bottoni, A Pontoglio, L Mastrototaro, B Giardina Expert opinion on investigational drugs 17 (10), 1533-1545, 2008 | 199 | 2008 |
| Mitochondria and cancer: a growing role in apoptosis, cancer cell metabolism and dedifferentiation. R Scatena Advances in Mitochondrial Medicine 942, 287, 2012 | 186 | 2012 |
| Pharmacological modulation of nitric oxide release: new pharmacological perspectives, potential benefits and risks R Scatena, P Bottoni, A Pontoglio, B Giardina Current medicinal chemistry 17 (1), 61-73, 2010 | 106 | 2010 |
| 3-(4-Aroyl-1-methyl-1 H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and/or-C4 substitutions on … A Mai, S Massa, I Cerbara, S Valente, R Ragno, P Bottoni, R Scatena, ... Journal of medicinal chemistry 47 (5), 1098-1109, 2004 | 94 | 2004 |
| Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential R Scatena, P Bottoni, GE Martorana, B Giardina Expert opinion on investigational drugs 14 (7), 835-846, 2005 | 93 | 2005 |
| Glycated human hemoglobin (HbA1c): functional characteristics and molecular modeling studies MC De Rosa, MT Sanna, I Messana, M Castagnola, A Galtieri, E Tellone, ... Biophysical chemistry 72 (3), 323-335, 1998 | 92 | 1998 |
| 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 3. Discovery of Novel Lead Compounds through … R Ragno, A Mai, S Massa, I Cerbara, S Valente, P Bottoni, R Scatena, ... Journal of medicinal chemistry 47 (6), 1351-1359, 2004 | 88 | 2004 |
| Binding Mode Analysis of 3-(4-Benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: A New Synthetic Histone Deacetylase Inhibitor Inducing Histone … A Mai, S Massa, R Ragno, M Esposito, G Sbardella, G Nocca, R Scatena, ... Journal of medicinal chemistry 45 (9), 1778-1784, 2002 | 86 | 2002 |
| The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing V Tesori, AC Piscaglia, D Samengo, M Barba, C Bernardini, R Scatena, ... Scientific reports 5 (1), 9149, 2015 | 84 | 2015 |
| Mitochondrial respiratory chain dysfunction, a non-receptor-mediated effect of synthetic PPAR-ligands: biochemical and pharmacological implications R Scatena, P Bottoni, GE Martorana, F Ferrari, P De Sole, C Rossi, ... Biochemical and Biophysical Research Communications 319 (3), 967-973, 2004 | 80 | 2004 |
| Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases R Scatena Expert Opinion on Investigational Drugs 9 (9), 2159-2165, 2000 | 76 | 2000 |
| An update on pharmacological approaches to neurodegenerative diseases R Scatena, GE Martorana, P Bottoni, G Botta, P Pastore, B Giardina Expert opinion on investigational drugs 16 (1), 59-72, 2007 | 74 | 2007 |
| The plasma membrane of erythrocytes plays a fundamental role in the transport of oxygen, carbon dioxide and nitric oxide and in the maintenance of the reduced state of the heme … MC De Rosa, CC Alinovi, A Galtieri, R Scatena, B Giardina Gene 398 (1-2), 162-171, 2007 | 58 | 2007 |
| Mitochondria, PPARs, and cancer: is receptor-independent action of PPAR agonists a key? R Scatena, P Bottoni, B Giardina PPAR research 2008, 2008 | 56 | 2008 |
| Immunological role of IgG subclasses C Napodano, MP Marino, A Stefanile, K Pocino, R Scatena, F Gulli, ... Immunological Investigations 50 (4), 427-444, 2021 | 55 | 2021 |
